In a separate email chain, FDA officials were told by an FDA vaccine safety analytic expert, Dr. Ana Szarfman, that the approach they were using to analyze the safety of COVID-19 vaccines was faulty. The information sparked a long discussion, during which officials considered | Collector

In a separate email chain, FDA officials were told by an FDA vaccine safety analytic expert, Dr. Ana Szarfman, that the approach they were using to analyze the safety of COVID-19 vaccines was faulty. The information sparked a long discussion, during which officials considered

The Epoch Times

In a separate email chain, FDA officials were told by an FDA vaccine safety analytic expert, Dr. Ana Szarfman, that the approach they were using to analyze the safety of COVID-19 vaccines was faulty. The information sparked a long discussion, during which officials considered

In a separate email chain, FDA officials were told by an FDA vaccine safety analytic expert, Dr. Ana Szarfman, that the approach they were using to analyze the safety of COVID-19 vaccines was faulty. The information sparked a long discussion, during which officials considered

Go to News Site